BIOPHARM FORWARD ApS: Financial statements 2023
CVR: 32438784
Source: annual report 2023, Danish Business Authority
26/08/2022 – 25/08/2023
BIOPHARM FORWARD ApS (CVR 32438784) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 549,847 and a net result of DKK -107,301 compared with DKK 156,128 the year before. That is a decrease of 5.9% compared with the year before. Equity in the 2023 report amounted to DKK 1,369,594. The solvency ratio was 80.5%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 549,847
- Profit/Loss
- DKK -107,301
- Equity
- DKK 1,369,594
- Total Assets
- DKK 1,701,739
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 550 t. | -107 t. | 1.4 mio. | 1 |
| 2022 | - | 584 t. | 156 t. | 1.6 mio. | 1 |
| 2021 | - | 928 t. | 1.5 mio. | 1.6 mio. | 1 |
| 2020 | - | 182 t. | 146 t. | 209 t. | 1 |
| 2019 | - | 291 t. | 201 t. | 171 t. | 0 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
BIOPHARM FORWARD ApS has published its annual report for 2022. Gross profit came to DKK 584,101, and the net result was DKK 156,128.
About BIOPHARM FORWARD ApS
BIOPHARM FORWARD ApS is a Danish company of the type Anpartsselskab based in Espergærde, founded in 2009. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The management consists of Jonas Hink. The company is owned by Jonas Hink. The company has 1 employee (2025). In 2025, the company reported a gross profit of DKK 997,234 and a net result of DKK 243,660 compared with DKK 385,061 the year before. Equity in the 2025 report amounted to DKK 1,741,315.